 |
 |
You won't be surprised to hear that we have done (more than one) analysis over the past many months, and it has become apparent throughout that the cost of the new drugs was always going to be more expensive than the cost of the entire warfarin monitoring service unless the price of dabigatran was set significantly lower than its current level. Clinicians are however being encouraged to 'think beyond the pricing issues' when considering prescribing dabigatran. I suspect that 'time in therapeutic range' on warfarin will prove to be one of the key factors when deciding who might benefit most from a change in prescription. Robert Dr Robert Treharne Jones Clinical Director Sullivan Cuff Software Limited -----Original Message----- From: GP-UK [mailto:[log in to unmask]] On Behalf Of Chris Markwick We are surgery that does in house anticoagulation monitoring.Has anyone done a practice cost analysis to see if its cheaper to switch to dabigatran & free up the nurses time to do other things? Currently prescribing isnt a real budget per se but its something the PCT keeps an eye on whereas staff costs are real.